Specificity of immunoglobulin high-throughput sequencing minimal residual disease monitoring in non-Hodgkin lymphomas.

"Conflict-of-interest disclosure: B.J.S. reports consultancy for Foresight Diagnostics. D.M.K. reports consultancy for Roche, Adaptive Biotechnologies, and Genentech and equity ownership interest in Foresight Diagnostics. S.K.A. reports speaker honoraria from Takeda. M.J.F. reports consultancy and research funding from 10.13039/100016796Adaptive Biotechnologies, research funding from Kite/10.13039/100005564Gilead, stock options from Allogene Therapeutics, and equity in Roche/Genentech. M.S.K. reports research funding from CRISPR Therapeutics and Nutcracker Therapeutics, and advisory committee membership for Myeloid Therapeutics and Daiichi Sankyo. M.D. reports research funding from 10.13039/100004325AstraZeneca, 10.13039/100004328Genentech, 10.13039/100007210Varian Medical Systems, and 10.13039/100010905Illumina; ownership interest in CiberMed and Foresight Diagnostics; and consultancy from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb (BMS), Genentech, Gritstone Oncology, Illumina, Novartis, and Roche. D.B.M. holds a patent with Pharmacyclics supporting ibrutinib for chronic graft-versus-host disease and receives consulting or research fees or serves as an advisor for Pharmacyclics, Kite Pharma, Adaptive Biotechnologies, Novartis, BMS, Janssen Pharmaceuticals, Roche, Genentech, Precision Bioscience, Allogene, Miltenyi Biotec, Fate Therapeutics, 2Seventy, and Adicet. A.A.A. reports consultancy for ADCT, Celgene, Chugai, Genentech, Gilead, Janssen, Pharmacyclics, and Roche; scientific advisory board membership in the Lymphoma Research Foundation; professional affiliations with the American Society of Hematology, American Society of Clinical Oncology, American Society of Clinical Investigation, and Leukemia & Lymphoma Society; research funding from the National Cancer Institute, 10.13039/100000050National Heart, Lung, and Blood Institute, National Institutes of Health, 10.13039/100006436Celgene, 10.13039/100002491BMS, and 10.13039/100004319Pfizer; patent filings, including patent issued, licensed, and with royalties paid from FortySeven, a patent pending and licensed to Foresight, a patent pending relating to MARIA, a patent issued and licensed to CiberMed, a patent issued, a patent pending to CiberMed, a patent issued to idiotype vaccines, and a patent issued, licensed, and with royalties paid from Roche; and equity ownership interests in CiberMed Inc, Foresight Diagnostics, FortySeven Inc, and CARGO Therapeutics. B.J.S. reports patent filings related to cancer biomarkers. D.M.K., M.D., and A.A.A. also report issued patents licensed to Foresight Diagnostics regarding cancer biomarkers and circulating tumor DNA. The remaining authors declare no competing interests."

"10.13039/100016796Adaptive Biotechnologies; Kite; 10.13039/100005564Gilead; CRISPR Therapeutics; Nutcracker Therapeutics; 10.13039/100004325AstraZeneca; 10.13039/100004328Genentech; 10.13039/100007210Varian Medical Systems; 10.13039/100010905Illumina; National Cancer Institute; 10.13039/100000050National Heart, Lung, and Blood Institute, National Institutes of Health; 10.13039/100006436Celgene; 10.13039/100002491BMS; 10.13039/100004319Pfizer"